57/100B253.440
USD
2.92
(1.17%)
Post Trading·252.400USD-1.040(-0.41%)
Last updated: · Delayed 15 min
Fair value393.86Plus-36%295Price 253.44492
Q4 FY2026 · Earnings report
EPS estimate 2.81Revenue estimate 2.61B
Q4 FY2026 · Earnings report
EPS estimate 2.81Revenue estimate 2.61B
If you had invested in Biogen ago, it would be worth $794 today, against $4,081 in SPY and $6,291 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
57/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash8
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation6.7
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth6
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength4
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders—
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Biogen key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Blend stock · 1.1/10Growth 1.1 · Value 1.0
- Day range
- 249.950 – 254.940
- 52-week range
- 153.770 – 258.780
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 37.46B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 107.39
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 5.90
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 2.36
- EPS growth forecast (FY2026)
- -18.2%
- Volume
- 53,015
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 0.17
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 69.4/100Environment 70 · Social 64 · Governance 74
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Christopher A. Viehbacher
- Employees
- 8K
- Website
- biogen.com
- IPO date
- 17 Sept 1991
Biogen earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
2.81 USD
Revenue estimate
2.61B USD
Last quarter · Q3 FY2026
EPS2.62Beat +31.7%Revenue2.80BBeat +6.4%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 4.19 | — | — | +60.01% | 2.73B | — | — | -2.61% | |
| Q2 FY2027 | 4.17 | — | — | +15.92% | 2.73B | — | — | -0.07% | |
| Q1 FY2027 | 3.55 | — | — | -0.52% | 2.63B | — | — | +6.19% | |
| Q4 FY2026 | 2.81 | — | — | +41.21% | 2.61B | — | — | +14.37% | |
| Q3 FY2026 | 1.99 | 2.62 | +31.66% | -45.53% | 2.63B | 2.80B | +6.43% | +14.23% | |
| Q2 FY2026 | 2.94 | 3.60 | +22.45% | -34.19% | 2.46B | 2.74B | +11.20% | +3.42% | |
| Q1 FY2026 | 3.05 | 3.57 | +17.05% | +18.21% | 2.29B | 2.48B | +8.35% | +1.93% | |
| Q4 FY2025 | 1.63 | 1.99 | +22.09% | -42.15% | 2.20B | 2.28B | +3.48% | -7.14% | |
| Q3 FY2025 | 3.88 | 4.81 | +23.97% | +17.89% | 2.34B | 2.45B | +4.91% | -0.45% | |
| Q2 FY2025 | 3.90 | 5.47 | +40.26% | +3.60% | 2.33B | 2.65B | +13.63% | +12.43% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 18.36 | — | — | +13.08% | 11.14B | — | — | +3.10% |
| FY2027 | 16.24 | — | — | +29.84% | 10.80B | — | — | +1.92% |
| FY2026 | 12.50 | — | — | -18.22% | 10.60B | — | — | +8.03% |
| FY2025 | 14.94 | 15.29 | +2.34% | -7.16% | 9.83B | 9.81B | -0.15% | +2.58% |
| FY2024 | 16.38 | 16.47 | +0.56% | +11.81% | 9.64B | 9.56B | -0.75% | -2.76% |
| FY2023 | 14.99 | 14.73 | -1.77% | -16.73% | 9.93B | 9.84B | -0.93% | -3.32% |
| FY2022 | 17.11 | 17.69 | +3.40% | -7.77% | 10.07B | 10.17B | +1.00% | -7.36% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Biogen analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
261.83 USD
+3.31%
Analysts' 1-year price targets range from 175.00 to 325.00, with an average of 261.83.
Past year
1-year forecast
Strong sellStrong buy
Buy
24 ratings
| Buy | 16 | |
| Hold | 7 | |
| Sell | 1 |
12-month price target
| Highest target | 325.00 |
| Average target | 261.83 |
| Lowest target | 175.00 |
| Current price | 253.44 |
Biogen valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 107.39
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 20.27
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 3.64
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 1.98
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 30.35
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
37.46B USD
+
Total debt
7.80B USD
−
Cash and short-term investments
1.30B USD
=
Enterprise value
43.96B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Biogen against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Bristol-Myers Squibb, Pfizer, Gilead Sciences, Amgen, and Organon &, the US Drug Manufacturers - General companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median107.410.1108.0
- Gross marginLowest in 5 years69.9%69.9%80.8%Against its peers: 5 of 6Peers' median 71.1%
- Operating marginLowest in 5 years19.0%19.0%28.4%Against its peers: 6 of 6Peers' median 28.5%
- Net marginBelow its median13.1%11.8%29.9%Against its peers: 4 of 6Peers' median 14.6%
- Return on equityLowest in 5 years7.1%7.1%22.7%Against its peers: 6 of 6Peers' median 37.5%
- Free cash flow marginAt its median20.7%11.2%30.8%Against its peers: 4 of 6Peers' median 22.0%
- Revenue growthHighest in 5 years2.2%-18.3%2.2%Against its peers: 3 of 6Peers' median -0.2%
- EPS growthAt its median-21.1%-61.8%100.7%Against its peers: 4 of 5Peers' median 42.3%
- Debt to EBITDAAbove its median2.36×1.87×3.09×Against its peers: 2 of 6Peers' median 3.23×
- Current ratioAbove its median2.681.352.99Against its peers: 1 of 6Peers' median 1.26
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Biogen growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 10.30B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 347.50M USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 70.05%
- Operating margin
- 7.64%
- Net margin
- 3.37%
Revenue / Net income
Revenue Net income Net margin
Biogen revenue breakdown
By product
FY2025
42.0%MS Product Revenues17.3%TYSABRI product16.1%SPINRAZA14.8%Fumarate9.8%Interferon
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| MS Product Revenues | 4.04B | 42.0% | -7.1% |
| TYSABRI product | 1.67B | 17.3% | -2.9% |
| SPINRAZA | 1.55B | 16.1% | -1.7% |
| Fumarate | 1.43B | 14.8% | -10.6% |
| Interferon | 945.60M | 9.8% | -2.3% |
By region
FY2025
60.1%Non-US39.9%United States
| Region | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Non-US | 3.57B | 60.1% | -10.2% |
| United States | 2.37B | 39.9% | -26.7% |
How Biogen makes its moneyWhat is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
Revenue9.89B 100.0%
Cost of revenue2.90B 29.3%
Gross profit6.91B 69.9%
Research and development1.95B 19.8%
Selling and administration2.43B 24.6%
Other operating expenses647.70M 6.5%
Operating income1.88B 19.0%
Tax108.11M 1.1%
Other expense476.00M 4.8%
Net income1.29B 13.1%
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.
Biogen financial health
- Cash and short-term investments
- 1.30B USD
- Total debt
- 7.80B USD
- Net cash
- -6.50B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.95
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.41
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 5 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 3.11
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Biogen ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 97.18%
- Institutional holders
- 1,103 (+40)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 99.25%
Who owns the shares
Institutions 97.2% Others 2.8%
As of 30 Jun 2026
Shares free to trade
Free float 146.70M shares ·99.2% Closely held 1.12M shares ·0.8%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 0 | 1.01K | 35.00 |
| Q3 2026 | 0 | 2 | 7.41K | 1.19K |
| Q2 2026 | 0 | 0 | 17.54K | 4.00K |
| Q1 2026 | 1 | 2 | 189.18K | 112.84K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: Biogen
Sector: Healthcare
Industry: Drug Manufacturers - General
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).